Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA4 | P22748 | 5/20 | 0.37 |
| ▸ | CA6 | P23280 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406518 | 1.00 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2LMNAPTGS1 | |
| SCHEMBL26460198 | 0.94 | CA1 (0.45) | NPC1RAB9ASMN1; SMN2LMNAPTGS1 | |
| SCHEMBL26460199 | 0.92 | KMT2A (0.47) | NPC1RAB9ASMN1; SMN2LMNAPTGS1 | |
| SCHEMBL17540097 | 0.86 | THRA (0.31) | CA1CA2CA4 | |
| SCHEMBL14799318 | 0.79 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2LMNAPTGS1 | |
| SCHEMBL24511059 | 0.77 | THRA (0.31) | — | |
| SCHEMBL19125184 | 0.76 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2LMNAPTGS1 | |
| SCHEMBL15198303 | 0.75 | — | — | |
| SCHEMBL21006006 | 0.75 | — | — | |
| SCHEMBL2689519 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20150191761-A1 | USE OF HIGH FLUX SCFA-DERIVATIZED MONOSACCHARIDES IN RECOMBINANT GLYCOPROTEIN PRODUCTION | THE JOHNS HOPKINS UNIVERSITY | 2015-07-09 | — | — | US | disclosed |
| US-8426585-B2 | Compounds comprising a spiro-ring | Xi, Ning (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2012-12-13 | — | — | US | disclosed |
| US-8293897-B2 | Compounds comprising a spiro-ring and methods of use | Xi, Ning (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-04-15 | — | — | US | disclosed |
| US-7462594-B2 | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-09 | — | — | US | disclosed |
| US-20080125375-A1 | PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-05-29 | — | — | US | disclosed |
| US-7304088-B2 | Peptide like compounds for treating coronavirus or hepatitis C virus; severe acute respiratory distress syndrome | TAIGEN BIOTECHNOLOGY (TW) | 2007-12-04 | — | — | US | disclosed |
| US-20050143320-A1 | Protease inhibitors | TAIGEN BIOTECHNOLOGY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093727-A1 | COMPOUNDS AND METHODS OF USE | PRKDC, PRKACA, PRKX | NPC1 1975/4885RAB9A 1903/4885SMN1; SMN2 3244/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | NPC1 4055/4885RAB9A 895/4885SMN1; SMN2 1910/4885 |
| US-20120315247-A1 | COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE | CDC42BPG, HRAS, PTPRJ | NPC1 2041/4885RAB9A 2254/4885SMN1; SMN2 3560/4885 |
| US-20150191761-A1 | USE OF HIGH FLUX SCFA-DERIVATIZED MONOSACCHARIDES IN RECOMBINANT GLYCOPROTEIN PRODUCTION | SLC35A1, FUT5, SLC17A5 | NPC1 1448/4885RAB9A 2512/4885SMN1; SMN2 3282/4885 |
| US-20050143320-A1 | Protease inhibitors | PREP, SPINT2, SERPINB1 | NPC1 1078/4885RAB9A 2489/4885SMN1; SMN2 2916/4885 |
| US-20080125375-A1 | PROTEASE INHIBITORS | PREP, SERPINB1, SPINT2 | NPC1 826/4885RAB9A 2403/4885SMN1; SMN2 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.